Real-world effectiveness and safety of tildrakizumab in Japanese patients with psoriasis: a single-center 52-week observational study
BackgroundReal-world data on the long-term effectiveness of tildrakizumab in Japanese patients with psoriasis remain limited, particularly in cohorts with relatively low baseline disease severity.ObjectivesTo evaluate the 52-week effectiveness and safety of tildrakizumab in a real-world Japanese cli...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Frontiers Media S.A.
2026-05-01
|
| Cyfres: | Journal of Cutaneous Immunology and Allergy |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.frontierspartnerships.org/articles/10.3389/jcia.2026.16442/full |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|